Telbermin

recombinant human vascular endothelial growth factor · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Telbermin, covering 2017-05-11 to 2017-05-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers [Phase 1]

See pricing